Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting

HIV Medicine

Volumn 15, Issue 7, 2014, Pages 417-424

  Macias J ^a,b   Recio, E ^a,b   Marquez M ^c   Garcia C ^d   Jimenez P ^e   Merino, D ^f   Munoz L ^g   Pasquau, J ^h   Ojeda, G ^c   Bancalero, P ^d   Chueca, N ^g   Pineda, Juan A ^a,b  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^d HOSPITAL DE JEREZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^f Unit of Infectious Diseases   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

CCR5 tropism; Darunavir; HIV; Maraviroc

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DARUNAVIR PLUS RITONAVIR; MARAVIROC; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOHEXANE DERIVATIVE; DARUNAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR; SULFONAMIDE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; ASTHENIA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TINGLING; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL TROPISM; VOMITING; DRUG ADMINISTRATION; DRUG COMBINATION; HIV INFECTIONS; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CCR5 RECEPTOR ANTAGONISTS; CYCLOHEXANES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TRIAZOLES;

EID: 84904035166     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12129     Document Type: Article

References (18)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2013. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (accessed 15 November 2013).
2. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-F32.
3. Joly V, Flandre P, Meiffredy V etal. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 2447-2454.
4. Cotter AG, Vrouenraets SM, Brady JJ etal. Impact of switching from zidovudine to tenofovirdisoproxilfumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 2013; 98: 1659-1666.
5. Ryom L, Mocroft A, Kirk O etal. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D Study. J Infect Dis 2013; 207: 1359-1369.
6. DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
7. Pulido F, Arribas JR, Delgado R etal. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22: F1-F9.
8. Arribas JR, Horban A, Gerstoft J etal. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24: 223-230.
9. Riddler SA, Haubrich R, DiRienzo AG etal. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-2106.
10. Okoli C, Siccardi M, Thomas-William S etal. Once daily maraviroc 300mg or 150mg in combination with ritonavir-boosted darunavir 800/100mg. J Antimicrob Chemother 2012; 67: 671-674.
11. Mora-Peris B, Croucher A, Else LJ etal. Pharmacokinetic profile and safety of 150mg of maraviroc dosed with 800/100mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects. J Antimicrob Chemother 2013; 68: 1348-1353.
12. Mills A, Mildvan D, Podzamczer D etal. Maraviroc once-daily nucleoside analog sparing regimen in treatment-naive patients: randomized, open-label pilot study. J Acquir Immune Defic Syndr 2013; 62: 164-170.
13. Taiwo B, Acosta EP, Ryscavage P etal. Virologic response, early HIV-1 decay, and maravirocpharmacokinetics with the nucleos(t)ide free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr 2013; 64: 167-173.
14. Comparative trial of maraviroc versus emtricitabine/tenofovir both with darunavir/ritonavir in antiretroviral-naive patients infected with CCR5 tropic HIV 1 (MODERN). NCT01345630. Available at http://clinicaltrials.gov (accessed 23 January 2014).
15. Chueca N, Garrido C, Alvarez M etal. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 2009; 81: 763-767.
16. Taiwo B, Lu D, Swindells S etal. Maraviroc + darunavir/ritonavir once daily exhibits rapid early viral decay: results of the viral dynamics sub-study of MIDAS. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6 2013, Atlanta, USA [Abstract 567].
17. Macías J, González J, Tural C etal. Prevalence and factors associated with liver steatosis measured by transient elastography with controlled attenuation parameter in HIV infection. 20th Conference on Retroviruses and Opportunistic Infections. March 3-6 2013, Atlanta, USA [Abstract 1051].
18. Macías J, Viloria MM, Rivero A etal. Lack of short-term increase in serum mediatorsoffibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis Cvirus-coinfected patients starting maraviroc-based antiretroviral therapy. Eur J ClinMicrobiol. Infect Dis 2012; 31: 2083-2088.